Tolazamide is a sulfonylurea used in the treatment of non insulin dependent diabetes mellitus. A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
- Mechanism
- Curator reviewed
Sulfonylureas likely bind to ATP-sensitive potassium-channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Depolarization stimulates calcium ion influx through voltage-sensitive calcium channels, raising intracellular concentrations of calcium ions, which induces the secretion, or exocytosis, of insulin.
- Primary indication
- For use as an adjunct to diet to lower the blood glucose in patients with non-insulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.Curator reviewed · 1 structured indication
- Formula / weight
- C14H21N3O3S · 311.4 g/mol (avg)
- First approval
- United States, 1995
- Code names
- AI3-50826 · BRN 1323565 · CCRIS 591 · EINECS 214-588-3 · HSDB 3192 · NCI-C03327 · NSC-70762 · U-17835
- Brand names
Resolves to
OUDSBRTVNLOZBN-UHFFFAOYSA-NSMILESCC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN1CCCCCC1What you can answer from here — as of September 12, 2026
Which drugs share a target with Tolazamide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account